Trade

with

Myriad Genetics Inc
(NASDAQ: MYGN)
AdChoices
35.03
-2.73
-7.23%
After Hours :
35.50
+0.47
+1.34%

Open

35.76

Previous Close

37.76

Volume (Avg)

2.77M (739.44k)

Day's Range

34.10-35.79

52Wk Range

20.02-42.50

Market Cap.

2.55B

Dividend Rate ( Yield )

-

Beta

0.99

Shares Outstanding

72.37M

P/E Ratio (EPS)

15.55 (2.25)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 778.22M

    • Net Income

    • 176.22M

    • Market Cap.

    • 2.55B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 22.64

    • PEG (Price/Earnings Growth) Ratio

    • 1.78

    • Beta

    • 0.99

    • Forward P/E

    • 17.76

    • Price/Sales

    • 3.52

    • Price/Book Value

    • 3.55

    • Price/Cash flow

    • 15.82

      • EBITDA

      • 288.26M

      • Return on Capital %

      • 21.65

      • Return on Equity %

      • 24.35

      • Return on Assets %

      • 21.65

      • Book Value/Share

      • 9.88

      • Shares Outstanding

      • 72.37M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Hold
        • 1 Year Price Target

        • 43.50

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • 2.30

        • Cashflow Estimate

        • 2.51

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 8.40

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • 19.80

          • -5.55

          • Net Income

            Q/Q (last year)

          • -23.70

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • 18.97

          • 47.82

          • Net Income

            5-Year Annual Average

          • 5.30

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 85.97

            • 42.70

            • Pre-Tax Margin

            • 35.71

            • 11.63

            • Net Profit Margin

            • 22.64

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • 87.20

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 37.90

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • 27.30

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 4.00

              • 1.23

              • Quick Ratio

              • 3.37

              • 0.76

              • Interest Coverage

              • -

              • 5.98

              • Leverage Ratio

              • 1.15

              • 2.16

              • Book Value/Share

              • 9.88

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 17.09

                • 31.85

                • P/E Ratio 5-Year High

                • 18.86

                • 325.07

                • P/E Ratio 5-Year Low

                • 6.26

                • 154.73

                • Price/Sales Ratio

                • 3.87

                • 2.21

                • Price/Book Value

                • 3.90

                • 2.88

                • Price/Cash Flow Ratio

                • 15.82

                • 18.15

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 24.35

                    (22.60)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • 21.65

                    (20.80)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • 24.35

                    (22.60)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • 106.87k

                  • 17.17k

                  • Inventory Turnover

                  • 7.55

                  • 5.07

                  • Asset Turnover

                  • 0.96

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  274.44M
                  Operating Margin
                  35.27
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  15.82
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  67.10%

                  Mutual Fund Ownership

                  71.27%

                  Float

                  62.30%

                  5% / Insider Ownership

                  1.72%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Royce Premier Fund

                  •  

                    5,969,565

                  • -5.90

                  • 8.20

                  • VA CollegeAmerica Small Cap World

                  •  

                    5,725,556

                  • 2.05

                  • 7.87

                  • VA CollegeAmerica New Economy

                  •  

                    2,962,495

                  • 1.36

                  • 4.07

                  • American Funds NVIT Growth

                  •  

                    2,735,000

                  • 80.04

                  • 3.76

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    1,759,344

                  • 0.00

                  • 2.37

                  • Undrly Baillie Giff Global Alpha Pen

                  •  

                    1,553,494

                  • 0.00

                  • 2.11

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,427,043

                  • 0.00

                  • 1.96

                  • Manulife Canadian Focused Fund

                  •  

                    1,312,281

                  • -0.36

                  • 1.79

                  • American Funds IS® Gbl Sm Cap

                  •  

                    1,274,898

                  • 5.11

                  • 1.75

                  • Vanguard Small Cap Index

                  •  

                    1,264,435

                  • -3.03

                  • 1.74

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Royce & Associates, LLC

                  •  

                    9,299,478

                  • -1.44%

                  • 12.65

                  • Baillie Gifford & Co Limited.

                  •  

                    8,785,503

                  • +1.37%

                  • 11.95

                  • Capital Research Global Investors

                  •  

                    8,717,609

                  • +3.42%

                  • 11.86

                  • Capital World Investors

                  •  

                    5,295,079

                  • +65.73%

                  • 7.20

                  • Vanguard Group, Inc.

                  •  

                    5,050,663

                  • +3.70%

                  • 6.87

                  • Scopia Management Inc.

                  •  

                    2,851,267

                  • +22.37%

                  • 3.88

                  • First Trust Advisors L.P.

                  •  

                    2,846,052

                  • +22.31%

                  • 3.87

                  • Iridian Asset Management LLC

                  •  

                    2,696,216

                  • +5.00%

                  • 3.67

                  • Tiger Technology Management LLC

                  •  

                    1,900,000

                  • -19.01%

                  • 2.59

                  • BlackRock Fund Advisors

                  •  

                    1,882,912

                  • -0.81%

                  • 2.56

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  Aggressive Growth

                  Style

                  Small Growth

                  Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide trea...moretment decisions and assess risk of disease progression and recurrence. The Companys business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patien...morets dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.lessless

                  Key People

                  Mr. Peter D. Meldrum

                  CEO/Director/President

                  Dr. John T. Henderson, M.D.

                  Chairman of the Board/Director

                  Dr. Walter Gilbert,PhD

                  Director/Vice Chairman of the Board

                  Mr. James S. Evans

                  CFO/Chief Accounting Officer/Treasurer

                  Mr. Robert G. Harrison

                  Chief Information Officer

                  • Myriad Genetics Inc

                  • 320 Wakara Way

                  • Salt Lake City, UT 84108

                  • USA.Map

                  • Phone: +1 801 584-3600

                  • Fax: +1 801 584-3640

                  • myriad.com

                  Incorporated

                  1991

                  Employees

                  1,649

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: